

# NHS Greater Glasgow and Clyde: New Medicines Decisions

## January 2016 to present

In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been:

- accepted for use in the NHSScotland by the Scottish Medicines Consortium (SMC), and/or
- accepted for use by the NHS board's Area Drug and Therapeutics Committee (ADTC).

## How does the NHS board decide which new medicines to make available for patients?

Each NHS board has an ADTC. The ADTC is responsible for advising the NHS board on all aspects of the use of medicines. ADTCs take account of national and, where applicable, local guidance when deciding which medicines should be routinely available.

## What national guidance does the ADTC consider?

- SMC advises on the use of newly licensed medicines in NHSScotland. In the table, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example Healthcare Improvement Scotland provides advice on some health technology assessments, including National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs).

## What local guidance does the ADTC consider?

- Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each NHS board provide advice to their ADTCs on which medicines can be routinely used. Sometimes clinical experts decide that established medicines are a better choice than new medicines.
- Medicines routinely available for use within an NHS board are usually included in the 'local formulary'. The formulary is a list of medicines for use in the NHS board that has been agreed by ADTC in consultation with local clinical experts. The formulary encourages prescribers to become familiar with a limited list of medicines which can be used to treat the majority of medical conditions.

## What if a particular medicine is not routinely available in my NHS board?

- This is usually because the medicine has not been accepted by SMC for use in NHSScotland.
- There may also be differences in which medicines are preferred in NHS boards. If SMC accepts a number of medicines for which there are other medicines already available to treat a specific medical condition, the NHS board's decision may depend on clinical experts' preferences and experiences with the medicine in their local population and on local prescribing guidance. If a decision is made for a medicine not to be routinely prescribed, there are usually alternative medicines available on the formulary.
- If a medicine is not routinely available and there are no suitable formulary alternatives, a doctor can make a request to prescribe the medicine if they believe it will benefit an individual patient. All NHS boards have procedures in place to consider individual requests when a doctor considers that a medicine not included on the formulary would be the best treatment option for an individual patient.

The following table lists the NHS board's decisions on new medicines.

If you need more information on medicines decisions in your NHS board area, please email [hcis.adtc-collaborative@nhs.net](mailto:hcis.adtc-collaborative@nhs.net)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Abatacept, Adalimumab, Etanercept, Tocilizumab</b>	Juvenile idiopathic arthritis - various licences with differing age limits	Available in line with national guidance	22/02/2016
TA373			
<b>Abiglutide</b> Eperzan®	Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.	Available in line with national guidance	22/02/2016
1024/15			
<b>Alendronic acid</b> Binosto®	Treatment of postmenopausal osteoporosis.	Available in line with national guidance	18/04/2016
1137/16			
<b>Ataluren</b> Translarna®	Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older.	Not available as not recommended for use in NHSScotland	18/04/2016
1131/16			
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>		
<b>Biologic agents (See below)</b>	Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) : medicines are adalimumab, certolizumab, etanercept, infliximab, golimumab	Available in line with national guidance	18/04/2016
MTA 383			
	<a href="https://www.nice.org.uk/guidance/ta383">https://www.nice.org.uk/guidance/ta383</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Biologic agents (see below)</b>	Rheumatoid arthritis (medicines are adalimumab, etanercept, infliximab, certolizumab, golimumab, abatacept, tocilizumab)	Available in line with national guidance	18/04/2016
MTA 375	<a href="https://www.nice.org.uk/guidance/ta375">https://www.nice.org.uk/guidance/ta375</a>		
<b>Camellia sinensis (green tea) leaf</b>	Cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years.	Available in line with national guidance	18/04/2016
Catephen®			
1133/16	<a href="http://http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>		
<b>Capsaicin</b>	Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain.	Not available as not recommended for use in NHSScotland	18/04/2016
Qutenza®			
1140/16			
<b>Daptomycin</b>	Treatment of paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections.	Not available as not recommended for use in NHSScotland	18/04/2016
Cubicin®			
1141/16			
<b>Dulaglutide</b>	In adults with type 2 diabetes mellitus to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.	Available in line with national guidance	22/02/2016
Trulicity®			
1110/15			

<b>Medicine</b>	<b>Condition being treated</b>	<b>NHSGGC Decision</b>	<b>Date of decision</b>
<b>Eculizumab</b> Soliris®  1130/16	In adults and children, for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Not available as not recommended for use in NHSScotland	18/04/2016
<b>Eculizumab</b> Soliris®  767/12	In adults and children for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS)	Not available as not recommended for use in NHSScotland	22/02/2016
<b>Enzalutamide</b> Xtandi  1066/15	Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1066_15_enzalutamide_Xtandi/Briefing_note_enzalutamide_Xtandi_IRP">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1066_15_enzalutamide_Xtandi/Briefing_note_enzalutamide_Xtandi_IRP</a>	Available in line with local guidance for prescribing	18/04/2016
<b>Eribulin (mesilate)</b> Halaven®  1065/15	Treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1065_15_eribulin_Halaven/Briefing_note_eribulin_Halaven_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1065_15_eribulin_Halaven/Briefing_note_eribulin_Halaven_Resubmission</a>	Available in line with local guidance for prescribing	18/04/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Erlotinib, Gefitinib</b>	Non-small cell lung cancer post chemotherapy	Available in line with national guidance	22/02/2016
TA374			
<b>Everolimus</b> Afinitor®	Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.	Available in line with local guidance for prescribing	18/04/2016
872/13	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>		
<b>Fulvestrant</b> Faslodex®	Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen.	Available in line with local guidance for prescribing	22/02/2016
114/04			
<b>Golimumab</b> Simponi®	Treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).	Available in line with national guidance	22/02/2016
1124/16			

<b>Medicine</b>	<b>Condition being treated</b>	<b>NHSGGC Decision</b>	<b>Date of decision</b>
<b>Guanfacine</b> Intuniv®  1123/16	Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 yrs old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1123_16_guanfacine_hydrochloride_Intuniv/Briefing_note_guanfacine_hydrochloride_Int">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1123_16_guanfacine_hydrochloride_Intuniv/Briefing_note_guanfacine_hydrochloride_Int</a>	Available in line with national guidance	18/04/2016
<b>Insulin detemir</b> Levemir®  1126/16	Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.	Available in line with national guidance	26/04/2016
<b>Isavuconazole</b> Cresemba®  1129/16	in adults for the treatment of: -invasive aspergillosis -mucormycosis in patients for whom amphotericin B is inappropriate  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Available in line with national guidance	18/04/2016
<b>Netupitant with Palonosetron</b> Akynzeo®  1109/15	Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in adult patients.	Available in line with local guidance for prescribing	22/02/2016
<b>Nivolumab</b> Opdivo®  1120/16	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/Briefing_note_nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/Briefing_note_nivolumab_Opdivo</a>	Not available as not recommended for use in NHSScotland	18/04/2016

<b>Medicine</b>	<b>Condition being treated</b>	<b>NHSGGC Decision</b>	<b>Date of decision</b>
<b>Oseltamivir</b> Tamiflu®  1127/16	Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.	Available in line with national guidance	26/04/2016
<b>Panobinostat</b> Farydak®  1122/16	In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.	Available in line with local guidance for prescribing	22/02/2016
<b>Pertuzumab</b> Perjeta®  1121/16	In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/Briefing_note_pertuzumab_Perjeta">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/Briefing_note_pertuzumab_Perjeta</a>	Not available as not recommended for use in NHSScotland	18/04/2016
<b>Pixantrone</b> Pixuvri®  1138/16	Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas	Not available as not recommended for use in NHSScotland	22/02/2016

<b>Medicine</b>	<b>Condition being treated</b>	<b>NHSGGC Decision</b>	<b>Date of decision</b>
<b>Sacubitril/Valsartan</b> Entresto®  1132/16	In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1132_16_sacubitril_valsartan_Entresto/Briefing_note_sacubitril_valsartan_Entresto">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1132_16_sacubitril_valsartan_Entresto/Briefing_note_sacubitril_valsartan_Entresto</a>	Available in line with local guidance for prescribing	18/04/2016
<b>Sorafenib</b> Nexavar®  482/08	Treatment of hepatocellular carcinoma	Available in line with local guidance for prescribing	22/02/2016
<b>Teduglutide</b> Revestive®  1139/16	Treatment of adult patients with Short Bowel Syndrome	Not available as not recommended for use in NHSScotland	22/02/2016
<b>Tolvaptan</b> Jinarc®  1114/15	To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.	Available in line with national guidance	22/02/2016
<b>Ulipristal acetate</b> Esmya®  1128/16	Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Available in line with national guidance	22/02/2016



<b>Medicine</b>	<b>Condition being treated</b>	<b>NHSGGC Decision</b>	<b>Date of decision</b>
<b>Ustekinumab</b> Stelara® 1115/15	Treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.	Available in line with national guidance	22/02/2016